Lili Jiang

Lili Jiang

Auto-generated profile, based on publicly available information

Lili Jiang

Phase I Clinical Trial Ward, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Cancer Letters
Verified
Journal Article
Closed access
SYsizhe yu
sizhe yu
YWYu Wang
Yu Wang
LJLi Jing
Li Jing
FCFrancois-xavier Claret
Francois-xavier Claret
QLQing Li
Qing Li
HGHui Guo
Hui Guo

3 November 2014 in Oncology Reports
Verified
Journal Article
Open access
PDF file
MWMin-Cong Wang
Min-Cong Wang
XLXuan Liang
Xuan Liang
ZLZhi-Yan Liu
Zhi-Yan Liu
JCJie Cui
Jie Cui
YLYing Liu
Ying Liu
YYYu Yao
Yu Yao
The concurrent administration of chemotherapy and epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) has previously produced a negative interaction and failed to confer a survival benefit to non‑small cell lung cancer (NSCLC) patients compared with first‑line cytotoxic chemotherapy. The present study aimed to investigate the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib in NSCLC cell lines and clarify the underlying mechanisms. HCC827, H1975, H1299 and A549 human NSCLC cell lines with wild‑type and mutant EGFR genes were used as in vitro models to define the differential effects of various schedules of cisplatin/paclitaxel with icotinib treatments on cell growth, proliferation, cell cycle distribution, apoptosis, and EGFR signaling pathway. Sequence‑dependent antiproliferative effects differed among the four NSCLC cell lines, and were not associated with EGFR mutation, constitutive expression levels of EGFR or downstream signaling molecules. The antiproliferative effect of cisplatin plus paclitaxel followed by icotinib was superior to that of cisplatin or paclitaxel followed by icotinib in the HCC827, H1975, H1299 and A549 cell lines, and induced more cell apoptosis and G0/G1 phase arrest. Cisplatin and paclitaxel significantly increased the expression of EGFR phosphorylation in the HCC827 cell line. However, only paclitaxel increased the expression of EGFR phosphorylation in the H1975 cell line. Cisplatin/paclitaxel followed by icotinib influenced the expression of p‑EGFR and p‑AKT, although the expression of p‑ERK1/2 remained unchanged. The results suggest that the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib differed among the NSCLC cell lines. The results also provide molecular evidence to support clinical treatment strategies for NSCLC patients.

7 August 2020 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
YBYiyang Bai
Yiyang Bai
XWXiao Wang
Xiao Wang
JHJia Hou
Jia Hou
LGLuying Geng
Luying Geng
XLXuan Liang
Xuan Liang
LJLili Jiang
Lili Jiang
Malignant pleural mesothelioma (MPM), predominantly caused by asbestos exposure, is a highly aggressive cancer with poor prognosis. The staging systems currently used in clinics is inadequate in evaluating the prognosis of MPM. In this study, a five-gene signature was developed and enrolled into a prognostic risk score model by LASSO Cox regression analysis based on two expression profiling datasets (GSE2549 and GSE51024) from Gene Expression Omnibus (GEO). The five-gene signature was further validated using the Cancer Genome Atlas (TCGA) MPM dataset. Univariate and multivariate Cox analyses proved that the five-gene signature was an independent prognostic factor for MPM. The signature remained statistically significant upon stratification by Brigham stage, AJCC stage, gender, tumor size, and lymph node status. Time-dependent receiver operating characteristic (ROC) curve indicated good performance of our model in predicting 1- and 2-years overall survival in MPM patients. The C-index was 0.784 for GSE2549 and 0.753 for the TCGA dataset showing moderate predictive accuracy of our model. Furthermore, Gene Set Enrichment Analysis suggested that the five-gene signature was related to pathways resulting in MPM tumor progression. Together, we have established a five-gene signature significantly associated with prognosis in MPM patients. Hence, the five-genes signature may serve as a potentially useful prognostic tool for MPM patients.

1 April 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
YLYanlin Li
Yanlin Li
HGHui Guo
Hui Guo
MLMengjie Liu
Mengjie Liu
ZZZehui Zhu
Zehui Zhu
HQHui Qiao
Hui Qiao
LJLili Jiang
Lili Jiang
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used medications in non-small cell lung cancer (NSCLC). We comprehensively evaluated the effect of NSAID exposure patterns on immunotherapy outcomes, prostaglandin E2 (PGE2) and immune cells. Methods: This multicenter study employed both prospective and retrospective approaches for patient enrollment. Patients were included if they had advanced NSCLC, and were first-time users of immune checkpoint inhibitor (ICI). Endpoints included progression-free survival (PFS) and overall survival (OS). Serum and tumor tissue were collected in the prospective subset for PGE2 and immune cell assay. Results: A total of 1,748 patients were included, with 232 patients prospectively enrolled. After multivariable adjustment, NSAID use was independently associated with improved PFS (HR 0.72, 95% CI 0.58 to 0.91, p=0.0053) and OS (HR=0.76, 95% CI 0.58 to 0.98, p=0.0364). Benefit was observed for both before-ICI (HR 0.75, 95 % CI 0.57 to 0.99, p=0.0383) and after-ICI initiation (HR 0.63, 95% CI 0.43 to 0.92, p=0.0159). For aspirin, low-dose aspirin users had better PFS than non-users (HR 0.69, 95% CI 0.51 to 0.94, p=0.0191), especially when used at least 30 days (HR=0.69, 95% CI 0.48 to 0.99, p=0.0464). Among non-selective NSAIDs, only after-ICI initiation improved OS (HR=0.49, 95% CI 0.24 to 0.99, p=0.0458). Any-grade (57.8% vs 53.4%) and grade ≥3 adverse events (9.2% vs 9.8%) were comparable among NSAID users and non-users. Serum sample indicated that aspirin was associated with less PGE2, which was related to better outcomes. On immune cells, RNA-seq revealed a correlation between the cyclooxygenase-2 pathway and neutrophils. Biosample analysis further demonstrated that aspirin use was associated with decreased neutrophils in both circulation and tumor. Conclusions: Long-term low-dose aspirin enhanced immunotherapy efficacy in patients with advanced NSCLC. PGE2 and neutrophils represented potential biomarkers guiding NSAID-immunotherapy integration. Trial registration number: NCT05754983 .

1 May 2014
Verified
Journal Article
Closed access
QGQianqian Guo
Qianqian Guo
ZLZhiyan Liu
Zhiyan Liu
LJLili Jiang
Lili Jiang
THTinghua Hu
Tinghua Hu
DLDongFan Li
DongFan Li
KNKejun Nan
Kejun Nan

9 March 2022 in Immunotherapy
Verified
Journal Article
Closed access
PJPanpan Jiang
Panpan Jiang
LGLuying Geng
Luying Geng
ZMZiyang Mao
Ziyang Mao
QWQinyang Wang
Qinyang Wang
WWWenjuan Wang
Wenjuan Wang
LJLili Jiang
Lili Jiang
Aim: To compare the efficacy and safety of first-line chemotherapy (Chemo) plus immune checkpoint inhibitors (ICIs) or bevacizumab (Bev) in advanced non-squamous non-small-cell lung cancer without ... Plain language summary Chemotherapy plus immune checkpoint inhibitors and chemotherapy plus bevacizumab were both superior to traditional chemotherapy and were recommended as the first-line treatme...